Clarametyx Biosciences, a Columbus, OH-based clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, received an investment from Kinetics AMR Accelerator Fund.
The amount of the deal, which extends the Series A funding completed in 2024, was not disclosed.
The company intends to use the funds to accelerate the ongoing CMTX-101 trial in cystic fibrosis-related infections in collaboration with the Cystic Fibrosis Foundation, and development of the CMTX-301 vaccine against recurrent bacterial infections, which was recently funded by CARB-X.
Led by CEO David Richards, Clarametyx Biosciences develops a technology platform targeting the biofilm, a protective layer around bacteria, to enable a more effective immune response and antibiotic intervention. The company is building a pipeline of immune-enabling therapies and vaccines for serious bacterial infections associated with biofilms, with a near-term focus on chronic respiratory diseases.
Aligned with the investment, KAMRA Venture Partner Douglas Thomson will join the Clarametyx Board of Directors.
FinSMEs
29/01/2025